Co-Authors
This is a "connection" page, showing publications co-authored by JASON B FLEMING and BINGBING DAI.
Connection Strength
1.971
-
Compound NSC84167 selectively targets NRF2-activated pancreatic cancer by inhibiting asparagine synthesis pathway. Cell Death Dis. 2021 07 10; 12(7):693.
Score: 0.800
-
Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarcinoma. Mol Cancer Ther. 2017 04; 16(4):662-670.
Score: 0.588
-
Hypoxia-induced autophagy of stellate cells inhibits expression and secretion of lumican into microenvironment of pancreatic ductal adenocarcinoma. Cell Death Differ. 2019 01; 26(2):382-393.
Score: 0.165
-
Transforming Growth Factor-? Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors. Clin Cancer Res. 2016 Oct 01; 22(19):4934-4946.
Score: 0.139
-
Regression of Stage IV Pancreatic Cancer to Curative Surgery and Introduction of a Novel Ex-Vivo Chemosensitivity Assay. Cureus. 2015 Dec 21; 7(12):e423.
Score: 0.136
-
Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition. Cancer Res. 2021 08 01; 81(15):4054-4065.
Score: 0.050
-
Oncogenic KRAS Recruits an Expansive Transcriptional Network through Mutant p53 to Drive Pancreatic Cancer Metastasis. Cancer Discov. 2021 08; 11(8):2094-2111.
Score: 0.049
-
Clinical candidate and genistein analogue AXP107-11 has chemoenhancing functions in pancreatic adenocarcinoma through G protein-coupled estrogen receptor signaling. Cancer Med. 2019 12; 8(18):7705-7719.
Score: 0.044